A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

Abstract Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib, dasatinib, bosutinib, nilotinib, and ponatinib) ta...

Full description

Bibliographic Details
Main Authors: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro, Jorge E. Cortes
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Journal of Hematology & Oncology
Subjects:
Chronic myeloid leukemia
Tyrosine kinase inhibitors
First-line treatment
Treatment switching
Treatment-free remission
Online Access:https://doi.org/10.1186/s13045-022-01309-0

Internet

https://doi.org/10.1186/s13045-022-01309-0

Similar Items